Modified low density lipoproteins differentially bind and activate the C1 complex of complement

Molecular Immunology

Volumn 44, Issue 6, 2007, Pages 1169-1177

  Biró, Adrienn ^a   Thielens, Nicole M ^b   Cervenák, László ^a   Prohászka, Zoltán ^a   Füst, George ^a   Arlaud, Gérard J ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUT DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Atherosclerosis; C1; Complement; LDL

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL ESTERASE; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEINASE;

ARTICLE; ATHEROSCLEROSIS; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; IN VIVO STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; SURFACE PLASMON RESONANCE;

ANIMALS; ATHEROSCLEROSIS; CATTLE; COMPLEMENT C1; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; LIPOPROTEINS, LDL; PROTEIN BINDING;

EID: 33748784075     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.06.013     Document Type: Article

References (31)

1. Alving C.R., Richards R.L., and Guirguis A.A. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J. Immunol. 118 (1977) 342-347
2. Arlaud G.J., Sim R.B., Duplaa A.-M., and Colomb M.G. Differential elution of C1q, C1r and C1s from human C1 bound to immune aggregates: use in the rapid purification of C1 subcomponents. Mol. Immunol. 16 (1979) 445-450
3. Arlaud G.J., Villiers C.L., Chesne S., and Colomb M.G. Purified proenzyme C1r: some characteristics of its activation and subsequent proteolytic cleavage. Biochim. Biophys. Acta 616 (1980) 116-129
4. Bhakdi S., Dorweiler B., Kirchmann R., Torzewski J., Weise E., Tranum-Jensen J., Walev I., and Wieland E. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J. Exp. Med. 182 (1995) 1959-1971
5. Bhakdi S., Torzewski M., Klouche M., and Hemmes M. Complement and atherogenesis: binding of CRP to degraded, non-oxidized LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2348-2354
6. Bhakdi S., Torzewski M., Paprotka K., Schmitt S., Barsoom H., Suriyaphol P., Han S.R., Lackner K.J., and Husmann M. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 109 (2004) 1870-1876
7. Buono C., Come C.E., Witztum J.L., Maguire G.F., Connelly P.W., Carroll M., and Lichtman A.H. Influence of C3 deficiency on atherosclerosis. Circulation 105 (2002) 3025-3031
8. Chang M.K., Binder C.J., Torzewski M., and Witztum J.L. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13043-13048
9. Chao F.F., Blanchette-Mackie E.J., Tertov V.V., Skarlatos S.I., Chen Y.J., and Kruth H.S. Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome. J. Biol. Chem. 267 (1992) 4992-4998
10. Henriksen T., Mahoney E.M., and Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 6499-6503
11. Lacroix M., Rossi V., Gaboriaud C., Chevallier S., Jacquinod M., Thielens N.M., Gagnon J., and Arlaud G.J. Structure and assembly of the catalytic region of human complement protease C1r: a three-dimensional model based on chemical cross-linking and homology modeling. Biochemistry 36 (1997) 6270-6282
12. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
13. Niculescu F., Rus H.G., and Vlaicu R. Activation of the human terminal complement pathway in atherosclerosis. Clin. Immunol. Immunopathol. 45 (1987) 147-155
14. Niculescu F., and Rus H. The role of complement activation in atherosclerosis. Immunol. Res. 30 (2004) 73-80
15. Ockene I.S., Matthews C.E., Rifai N., Ridker P.M., Reed G., and Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin. Chem. 47 (2001) 444-450
16. Reboul A., Arlaud G.J., Sim R.B., and Colomb M.G. A simplified procedure for the purification of C1-inactivator from human plasma. FEBS Lett. 79 (1977) 45-50
17. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
18. Savay S., Szebeni J., Baranyi L., and Alving C.R. Potentiation of liposome-induced complement activation by surface bound albumin. Biochim. Biophys. Acta 1559 (2002) 79-86
19. Schmiedt W., Kinscherf R., Deigner H.P., Kamencic H., Nauen O., Kilo J., Oelert H., Metz J., and Bhakdi S. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1790-1795
20. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272 (1997) 20963-20966
21. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low density lipoprotein that increase its atherogenecity. N. Engl. J. Med. 320 (1989) 915-924
22. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., and Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 3883-3887
23. Tacnet-Delorme P., Chevallier S., and Arlaud G.J. β-Amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for Aβ on the C1q globular regions. J. Immunol. 167 (2001) 6374-6381
24. Taskinen S., Kovanen P.T., Jarva H., Meri S., and Pentikainen M.O. Binding of C-reactive protein to modified low density lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem. J. 367 (2002) 403-412
25. Torzewski M., Klouche M., Hock J., Messner M., Dorweiler B., Torzewski J., Gabbert H.E., and Bhakdi S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 369-378
26. Torzewski M., Suriyaphol P., Paprotka K., Spath L., Ochsenhirt V., Schmitt A., Han S.-R., Husmann M., Gerl V.B., Bhakdi S., and Lackner K.J. Enzymatic modification of low density lipoprotein in the arterial wall. A new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2130-2136
27. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 38 (2001) 189-197
28. Wieland E., Parthasarathy S., and Steinberg D. Peroxidase-dependent metal-independent oxidation of low density lipoprotein in vitro: a model for in vivo oxidation?. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 5929-5933
29. Wieland E., Dorweiler B., Bonitz U., Lieser S., Walev I., and Bhakdi S. Complement activation by oxidatively modified low density lipoproteins. Eur. J. Clin. Invest. 29 (1999) 835-841
30. Ziccardi R.J. A new role for C1-inhibitor: control of activation of the first component of human complement. J. Immunol. 128 (1982) 2505-2508
31. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197